Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Review of the evidence in relation to the treatment criteria for Ibrutinib: Letter from Professor Peter Clark – NHS England

This letter, sent to Professor Stephen Powis, provides information about the re-examination of the commissioning treatment criteria for the use of ibrutinib in previously treated patients with chronic lymphocytic leukaemia (CLL).

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma: Technology appraisal guidance [TA524] – NICE

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults. This guidance is a Cancer Drugs Fund reconsideration of brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446). This guidance replaces TA446.  

Arsenic trioxide for treating acute promyelocytic leukaemia: Technology appraisal guidance [TA526] – NICE

Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.  

Patient access to ibrutinib for previously treated chronic lymphocytic leukaemia in England – NHS England

This clinical statement gives details about patient access to ibrutinib for chronic lymphocytic leukaemia. It states NHS is funding the cancer drug in line with NICE recommendations.

The Hidden Cancer: The Need to Improve Blood Cancer Care – All-Parliamentary Group on Blood Cancer

All-Parliamentary Group on Blood Cancer report that makes important recommendations on how to make improvements and ensure that we all work together to raise awareness of blood cancer. It is also a call to the Government and NHS to ensure